These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23800901)

  • 1. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.
    Carlier M; Noë M; De Waele JJ; Stove V; Verstraete AG; Lipman J; Roberts JA
    J Antimicrob Chemother; 2013 Nov; 68(11):2600-8. PubMed ID: 23800901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.
    Carlier M; Noë M; Roberts JA; Stove V; Verstraete AG; Lipman J; De Waele JJ
    J Antimicrob Chemother; 2014 Oct; 69(10):2797-803. PubMed ID: 24917580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children.
    De Cock PA; Standing JF; Barker CI; de Jaeger A; Dhont E; Carlier M; Verstraete AG; Delanghe JR; Robays H; De Paepe P
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7027-35. PubMed ID: 26349821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.
    de Velde F; de Winter BC; Koch BC; van Gelder T; Mouton JW;
    J Antimicrob Chemother; 2016 Oct; 71(10):2909-17. PubMed ID: 27330071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of high-flux haemodialysis on the probability of target attainment for oral amoxicillin/clavulanic acid combination therapy.
    Hui K; Patel K; Kong DCM; Kirkpatrick CMJ
    Int J Antimicrob Agents; 2017 Jul; 50(1):110-113. PubMed ID: 28502697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.
    De Velde F; De Winter BCM; Koch BCP; Van Gelder T; Mouton JW;
    J Antimicrob Chemother; 2018 Feb; 73(2):469-476. PubMed ID: 29136160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration.
    Escobar L; Andresen M; Downey P; Gai MN; Regueira T; Bórquez T; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Aug; 44(2):163-7. PubMed ID: 24837847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the standard dose of amoxicillin-clavulanic acid sufficient?
    Haeseker M; Havenith T; Stolk L; Neef C; Bruggeman C; Verbon A
    BMC Pharmacol Toxicol; 2014 Jul; 15():38. PubMed ID: 25047044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
    Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
    Sandri AM; Landersdorfer CB; Jacob J; Boniatti MM; Dalarosa MG; Falci DR; Behle TF; Bordinhão RC; Wang J; Forrest A; Nation RL; Li J; Zavascki AP
    Clin Infect Dis; 2013 Aug; 57(4):524-31. PubMed ID: 23697744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration.
    Roberts JA; Udy AA; Bulitta JB; Stuart J; Jarrett P; Starr T; Lassig-Smith M; Roberts NA; Dunlop R; Hayashi Y; Wallis SC; Lipman J
    J Antimicrob Chemother; 2014 Sep; 69(9):2508-16. PubMed ID: 24879665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and dosing simulations of amoxicillin in obese adults receiving co-amoxiclav.
    Mellon G; Hammas K; Burdet C; Duval X; Carette C; El-Helali N; Massias L; Mentré F; Czernichow S; Crémieux AC
    J Antimicrob Chemother; 2020 Dec; 75(12):3611-3618. PubMed ID: 32888018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and oral bioavailability of amoxicillin and clavulanic acid in pigs.
    Reyns T; De Boever S; Baert K; Croubels S; Schauvliege S; Gasthuys F; De Backer P
    J Vet Pharmacol Ther; 2007 Dec; 30(6):550-5. PubMed ID: 17991223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
    Torrico M; Aguilar L; González N; Giménez MJ; Echeverría O; Cafini F; Sevillano D; Alou L; Coronel P; Prieto J
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3699-706. PubMed ID: 17664320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.